References
- de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16:203–4
- de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 2016;19:313–15
- Writing Group for the Women’s Health Initiative. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Baber RJ, Panay N, Fenton A, and the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
- Menopause: diagnosis and management. NICE Guidelines, November 2015. https://www.nice.org.uk/guidance/ng23
- Panay N, Fenton A. A global consensus statement on menopause hormone therapy – aims, aspirations and action points. Climacteric 2013;16:201–2